Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.
Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, Günthard HF, De Wit S, Guaraldi G, Vehreschild JJ, Wit F, Law M, Wasmuth JC, Chkhartishvili N, d'Arminio Monforte A, Fontas E, Vesterbacka J, Miro JM, Castagna A, Stephan C, Llibre JM, Neesgaard B, Greenberg L, Smith C, Kirk O, Duvivier C, Dragovic G, Lundgren J, Dedes N, Knudsen A, Gallant J, Vannappagari V, Peters L, Elbirt D, Sarcletti M, Braun DL, Necsoi C, Mussini C, Muccini C, Bolokadze N, Hoy J, Mocroft A, Ryom L. Bansi-Matharu L, et al. Lancet HIV. 2021 Nov;8(11):e711-e722. doi: 10.1016/S2352-3018(21)00163-6. Epub 2021 Sep 20. Lancet HIV. 2021. PMID: 34555326
Sustainable HIV treatment in Africa through viral-load-informed differentiated care.
Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa; Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren JD, Eaton JW, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo KJ, van de Vijver D, Wilson DP, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson LJ, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett TB, Revill P. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, et al. Nature. 2015 Dec 3;528(7580):S68-76. doi: 10.1038/nature16046. Nature. 2015. PMID: 26633768 Free PMC article.
Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa.
Phillips AN, Cambiano V, Revill P, Nakagawa F, Lundgren JD, Bansi-Matharu L, Mabugu T, Sculpher M, Garnett G, Staprans S, Becker S, Murungu J, Lewin SR, Deeks SG, Hallett TB. Phillips AN, et al. J Infect Dis. 2016 Jul 1;214(1):73-9. doi: 10.1093/infdis/jiw120. Epub 2016 Mar 30. J Infect Dis. 2016. PMID: 27034345 Free PMC article.
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A. Phillips AN, et al. Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29. Lancet HIV. 2019. PMID: 30503325 Free PMC article.
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting.
Greenberg L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, Öllinger A, Neesgaard B, Stephan C, Calmy A, Rauch A, Castagna A, Spagnuolo V, Johnson M, Stingone C, Mussini C, De Wit S, Necsoi C, Campins AA, Pradier C, Stecher M, Wasmuth JC, Monforte AD, Law M, Puhr R, Chkhartishvilli N, Tsertsvadze T, Garges H, Thorpe D, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND Study Group. Greenberg L, et al. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):240-250. doi: 10.1097/QAI.0000000000002250. J Acquir Immune Defic Syndr. 2020. PMID: 31923088 Free article.
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S. Phillips AN, et al. Lancet HIV. 2020 Mar;7(3):e193-e200. doi: 10.1016/S2352-3018(19)30400-X. Epub 2020 Feb 5. Lancet HIV. 2020. PMID: 32035041 Free PMC article.
44 results